At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 68 enrolled
Drug / intervention
Lasmiditan +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Randomized, Subject- and Investigator-Blind, Placebo-Controlled, 4-Period Cross-Over Study Assessing the Duration of Effect of Lasmiditan on Simulated Driving Performance in Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating Lasmiditan, Placebo, and 1 other intervention for Healthy. Completed, enrolled 68 participants across 3 sites.
Detailed Summary
The purpose of this study is to evaluate the effect of lasmiditan on simulated driving performance in healthy participants. Participants are expected to complete each of four study periods, which will last a total of about 10 days. During this time, participants will remain in the clinical research unit. Screening must be completed within 28 days before the start of the study. Follow-up will be completed about one week after discharge.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedMar 2018
Enrollment StartMar 2018
Primary CompletionJun 2018
TodayJul 2026
First PostedMar 9, 2018
Enrollment StartMar 26, 2018
Primary CompletionJun 23, 2018
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 8.3 years ago
Interventions
Lasmiditandrug
Administered orally
Placebodrug
Administered orally
Diphenhydraminedrug
Administered orally